Anderson Fisher LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 66,447 shares of the company’s stock after selling 1,728 shares during the period. Novo Nordisk A/S makes up approximately 1.3% of Anderson Fisher LLC’s portfolio, making the stock its 12th biggest holding. Anderson Fisher LLC’s holdings in Novo Nordisk A/S were worth $3,476,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the business. GYL Financial Synergies LLC purchased a new position in Novo Nordisk A/S during the first quarter worth approximately $1,090,000. TCG Advisors LP purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $27,000. Westwood Holdings Group Inc. raised its stake in shares of Novo Nordisk A/S by 205.3% in the 1st quarter. Westwood Holdings Group Inc. now owns 47,065 shares of the company’s stock valued at $2,462,000 after acquiring an additional 31,649 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $49,039,000. Finally, Qtron Investments LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $231,000. 7.15% of the stock is currently owned by institutional investors.
NVO has been the topic of a number of research reports. Pareto Securities downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Credit Suisse Group raised shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Wednesday, February 13th. Finally, Barclays raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 target price on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $52.15.
NVO opened at $51.59 on Wednesday. The firm has a market cap of $126.11 billion, a P/E ratio of 20.47, a PEG ratio of 2.23 and a beta of 0.58. Novo Nordisk A/S has a twelve month low of $41.23 and a twelve month high of $52.83. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 0.07.
Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Friday, May 3rd. The company reported $0.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.04. The business had revenue of $4.46 billion during the quarter, compared to analyst estimates of $4.35 billion. Novo Nordisk A/S had a net margin of 33.60% and a return on equity of 78.28%. Equities analysts forecast that Novo Nordisk A/S will post 2.43 earnings per share for the current year.
WARNING: “Novo Nordisk A/S (NYSE:NVO) Holdings Trimmed by Anderson Fisher LLC” was first posted by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://theenterpriseleader.com/2019/06/12/novo-nordisk-a-s-nysenvo-holdings-trimmed-by-anderson-fisher-llc.html.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Recommended Story: What are the most popular ETFs
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.